Zongyu Liu

Nov 28, 2024 | onlinelibrary.wiley.com | Zongyu Liu |Hongyu Chu |Weidong Zhao |Chenguang Yang

1 Introduction Opdivo (nivolumab) plus Yervoy (ipilimumab) is dual immunotherapy targeting and blocking the immune checkpoints PD1 and CTLA-4, and has been successfully applied in clinical cancer therapy,[1] including colorectal cancer,[2] hepatocellular carcinoma,[3] and non-small cell carcinoma.[4] Less than 30% of cancer patients respond to immune checkpoint therapy, but treatment with Opdivo plus Yervoy at an optimum dosage ratio of 3:1 enhances antitumor efficacy.

May 13, 2024 | cell.com | Qinqin Cui |Zongyu Liu |Ge Bai |Liangzhu Laboratory

Alberts B. Johnson A. Lewis J. Raff M. Roberts K. Walter P. Molecular Biology of the Cell. Fifth Edition. W.W. Norton & Company, 2007https://doi.org/10.1201/9780203833445Hirose T. Ninomiya K. Nakagawa S. Yamazaki T. A guide to membraneless organelles and their various roles in gene regulation. Nat. Rev. Mol. Cell Biol. 2023; 24: 288-304https://doi.org/10.1038/s41580-022-00558-8Brangwynne C.P. Eckmann C.R. Courson D.S. Rybarska A. Hoege C. Gharakhani J. Jülicher F.